Media Summary: Dr Michael Mack (Baylor Scott & White Heart Hospital, Plano, US) joins us to share the clinical and echocardiographic outcomes ... Dr Michael J Mack (Baylor Scott & White Heart Hospital, Plano, TX, US) discusses the two-year clinical and echocardiographic ... Dr. Lars Svensson, Chairman of the Heart and Vascular Institute and Dr. Samir Kapadia, Section Head, Interventional Cardiology ...

Partner 3 Trial - Detailed Analysis & Overview

Dr Michael Mack (Baylor Scott & White Heart Hospital, Plano, US) joins us to share the clinical and echocardiographic outcomes ... Dr Michael J Mack (Baylor Scott & White Heart Hospital, Plano, TX, US) discusses the two-year clinical and echocardiographic ... Dr. Lars Svensson, Chairman of the Heart and Vascular Institute and Dr. Samir Kapadia, Section Head, Interventional Cardiology ... Mirvat Alasnag interviews Michael J. Mack about the seven-year clinical and echocardiographic outcomes of the Martin Leon, MD and Michael Mack, MD provide an overview of the results of No audio (I have been too busy lately but I promise I'll do this at some point!) You can download the slides here: ...

Watch the full video on Radcliffe Cardiology here: ... Dr. Peter Block and Dr. Craig Smith discuss the Alex Sticchi interviews Martin Leon about the five-year clinical and echocardiographic outcomes from the In this short virtual interview, we are joined by Dr Martin B Leon (Columbia University Medical Center, US) to discuss the 5-year ... In structural cardiology, TAVI has been further validated for low-risk patients. The most recent

Photo Gallery

TCT 25: Seven-Year Follow-up of the PARTNER 3 Trial: Clinical and Echocardiographic Outcomes
ACC 2020: Updates from the PARTNER 3 Trial — Dr Michael J Mack
Overview of PARTNER 3 & Evolut Low Risk TAVR Trials
PARTNER 3: Lessons learned and impact on future patient care
PARTNER 3 Low-Risk: Seven-year clinical and echocardiographic outcomes of TAVR vs. SAVR #TCT2025
PARTNER 3 Trial
PARTNER 3 trial journal club slides
TCT 2021: PARTNER 3: TAVR is Cost Effective Compared with SAVR for Low-Risk Patients
PARTNER Trial
PARTNER 3 Low-Risk trial: 5-year insights on TAVI vs. SAVR outcomes
TCT 23: 5Y Outcomes From the PARTNER 3 Low-Risk Trial
Seven-year outcomes of the PARTNER 3 Low-risk trial - TCT 2025
View Detailed Profile
TCT 25: Seven-Year Follow-up of the PARTNER 3 Trial: Clinical and Echocardiographic Outcomes

TCT 25: Seven-Year Follow-up of the PARTNER 3 Trial: Clinical and Echocardiographic Outcomes

Dr Michael Mack (Baylor Scott & White Heart Hospital, Plano, US) joins us to share the clinical and echocardiographic outcomes ...

ACC 2020: Updates from the PARTNER 3 Trial — Dr Michael J Mack

ACC 2020: Updates from the PARTNER 3 Trial — Dr Michael J Mack

Dr Michael J Mack (Baylor Scott & White Heart Hospital, Plano, TX, US) discusses the two-year clinical and echocardiographic ...

Overview of PARTNER 3 & Evolut Low Risk TAVR Trials

Overview of PARTNER 3 & Evolut Low Risk TAVR Trials

Dr. Vinod H. Thourani gives the

PARTNER 3: Lessons learned and impact on future patient care

PARTNER 3: Lessons learned and impact on future patient care

Dr. Lars Svensson, Chairman of the Heart and Vascular Institute and Dr. Samir Kapadia, Section Head, Interventional Cardiology ...

PARTNER 3 Low-Risk: Seven-year clinical and echocardiographic outcomes of TAVR vs. SAVR #TCT2025

PARTNER 3 Low-Risk: Seven-year clinical and echocardiographic outcomes of TAVR vs. SAVR #TCT2025

Mirvat Alasnag interviews Michael J. Mack about the seven-year clinical and echocardiographic outcomes of the

PARTNER 3 Trial

PARTNER 3 Trial

Martin Leon, MD and Michael Mack, MD provide an overview of the results of

PARTNER 3 trial journal club slides

PARTNER 3 trial journal club slides

No audio (I have been too busy lately but I promise I'll do this at some point!) You can download the slides here: ...

TCT 2021: PARTNER 3: TAVR is Cost Effective Compared with SAVR for Low-Risk Patients

TCT 2021: PARTNER 3: TAVR is Cost Effective Compared with SAVR for Low-Risk Patients

Watch the full video on Radcliffe Cardiology here: ...

PARTNER Trial

PARTNER Trial

Dr. Peter Block and Dr. Craig Smith discuss the

PARTNER 3 Low-Risk trial: 5-year insights on TAVI vs. SAVR outcomes

PARTNER 3 Low-Risk trial: 5-year insights on TAVI vs. SAVR outcomes

Alex Sticchi interviews Martin Leon about the five-year clinical and echocardiographic outcomes from the

TCT 23: 5Y Outcomes From the PARTNER 3 Low-Risk Trial

TCT 23: 5Y Outcomes From the PARTNER 3 Low-Risk Trial

In this short virtual interview, we are joined by Dr Martin B Leon (Columbia University Medical Center, US) to discuss the 5-year ...

Seven-year outcomes of the PARTNER 3 Low-risk trial - TCT 2025

Seven-year outcomes of the PARTNER 3 Low-risk trial - TCT 2025

In structural cardiology, TAVI has been further validated for low-risk patients. The most recent

Live from #ACC19: Results of the PARTNER 3 Trial

Live from #ACC19: Results of the PARTNER 3 Trial

Michael Mack, M.D., an author on the